Stocktoria
Processa Pharmaceuticals, Inc. PCSA
Processa Pharmaceuticals, Inc. financials (annual)
Bars are annual figures from 2016 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | $0 | $0 | — | — | — | — | $5,000 |
| Gross profit | — | — | — | — | — | — | — | — | — | $5,000 |
| R&D expense | — | — | $5.8M | $11.5M | $6.9M | $3.2M | $2.3M | $3.1M | $964,164 | $1.5M |
| SG&A expense | — | — | — | — | — | — | — | $1.4M | $838,269 | $69,968 |
| Operating income | -$14.0M | -$12.1M | -$11.5M | -$27.5M | -$12.1M | -$15.1M | -$3.9M | -$4.5M | -$1.8M | -$1.9M |
| Interest expense | — | — | — | — | $362 | $281,122 | $36,658 | $161,205 | $59,063 | $245,384 |
| Income tax | — | — | — | — | -$530,611 | -$1.0M | -$602,716 | -$902,801 | $258,583 | — |
| Net income | -$13.6M | -$11.9M | -$11.1M | -$27.4M | -$11.4M | -$14.4M | -$3.4M | -$3.8M | -$1.9M | -$1.9M |
| EPS (diluted) | $-10.36 | $-96.78 | $-8.48 | $-34.05 | — | — | — | — | $-0.06 | $-0.07 |
| Operating cash flow | -$11.4M | -$11.2M | -$8.1M | -$9.6M | -$8.7M | -$3.1M | -$2.8M | -$3.7M | -$1.7M | -$2.2M |
| Free cash flow | — | -$11.2M | -$8.1M | — | — | — | — | — | -$1.7M | -$2.2M |
| Cash & equivalents | $5.5M | $1.2M | $4.7M | $6.5M | $16.5M | $15.4M | $691,536 | $1.7M | $2.8M | $1.1M |
| Total assets | $7.8M | $3.2M | $5.8M | $8.6M | $26.5M | $25.2M | $10.9M | $12.5M | $3.0M | $2.4M |
| Total liabilities | $2.2M | $1.5M | $797,484 | $1.1M | $978,405 | $2.3M | $2.9M | $2.8M | $2.6M | $97,692 |
| Shareholders' equity | $5.6M | $1.7M | $5.0M | $7.5M | $25.5M | $22.9M | $8.0M | $9.7M | $373,163 | -$2.3M |
Growth · year-over-year
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth | — | — | — | — | — | — | — | — | — | -95.6% |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.